Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 4411 AL 4425

Reply: "Navigating the Neuropsychiatric Risks of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease"

Hauw F, Méneret A, Mantisi L, Letrillart H, Grabli D, Brohée S, Roze E.

Mov Disord Clin Pract. 2025 Nov;12(11):2030-2031. doi: 10.1002/mdc3.70331. Epub 2025 Sep 1.

Motor features that distinguish isolated REM sleep behavior disorder patients from healthy controls: A systematic review

Elasfar S, Hameed H, Ehgoetz Martens K.

J Parkinsons Dis. 2025 Nov;15(7):1155-1193. doi: 10.1177/1877718X251359225. Epub 2025 Sep 1.

Developing personalized treatment strategies for Parkinson's disease based on disease subtypes

Hey GE, Eisinger R, Guarin D, Safarpour D, Rodríguez-Violante M, Ramirez-Zamora A.

Expert Rev Neurother. 2025 Oct;25(10):1175-1194. doi: 10.1080/14737175.2025.2552784. Epub 2025 Sep 1.

Parkinson's disease incidence in glaucoma patients from israel: insights from a 20-year follow-up sample

Kozlov Y, Geffen N, Shulman S, Zahavi A, Gal-Or O, Dotan A, Gazit S, Patalon T, Meshi A.

Graefes Arch Clin Exp Ophthalmol. 2025 Dec;263(12):3471-3481. doi: 10.1007/s00417-025-06953-z. Epub 2025 Sep 1.

A systematic review of natural products targeting Nrf2-Keap1-ARE pathway and their influence on neurodegenerative disorders

Gote S, Dubey S, Nargund SL, Thapa S.

Inflammopharmacology. 2025 Sep;33(9):5097-5111. doi: 10.1007/s10787-025-01917-5. Epub 2025 Sep 1.

Interventions for preventing falls in older people in care facilities

Dyer SM, Kwok WS, Suen J, Dawson R, Kneale D, Sutcliffe K, Seppala LJ, Hill KD, Kerse N, Murray GR, van der Velde N, Sherrington C, Cameron ID.

Cochrane Database Syst Rev. 2025 Aug 20;8(8):CD016064. doi: 10.1002/14651858.CD016064.

Recent Insights in Multi-Target Drugs in Pharmacology and Medicinal Chemistry

Cemali SH, Poyraz S, Belveren S, Taş S, Tamer MA, Döndaş NY, Döndaş HA, Sansano JM.

ChemMedChem. 2025 Sep 25;20(18):e202500447. doi: 10.1002/cmdc.202500447. Epub 2025 Sep 1.

Sulfonamide Inhibitors of Amyloid Aggregation: A Promising Path against Neurodegenerative Diseases

Smirnovienė J, Matulis D.

ChemMedChem. 2025 Oct 6;20(19):e202500324. doi: 10.1002/cmdc.202500324. Epub 2025 Sep 1.

Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial

Schiess MC, Suescun J, Martinez-Lemus JD, Green C, Thomas TS, Shahnawaz M, Tharp E, Satani NB, Saltarrelli JG, Adams C, Doursout MF, Thyne V, Abuamouneh R, Rodarte EM, Savitz SI, Ellmore TM.

Mov Disord. 2025 Dec;40(12):2688-2699. doi: 10.1002/mds.70028. Epub 2025 Sep 1.

Improving the Study of Impulse Control Disorders in CSAI-Treated Parkinson's Disease: Methodological and Interdisciplinary Directions

Wang Y, He Y, Cai H.

Mov Disord Clin Pract. 2025 Dec;12(12):2390-2391. doi: 10.1002/mdc3.70316. Epub 2025 Sep 2.

Reply: "Improving the Study of Impulse Control Disorders in CSAI-Treated Parkinson's Disease: Methodological and Interdisciplinary Directions"

Desjardins C, Bastos PAD, Fabbri M.

Mov Disord Clin Pract. 2025 Dec;12(12):2392-2393. doi: 10.1002/mdc3.70315. Epub 2025 Sep 2.

Patients with small fiber neuropathy exhibit more pronounced non-motor symptoms in Parkinson's disease

Xie C, Chen J, Gan R, Gao Y, Wang L, Ma G, Zhang Y, Nie K, Wang L.

J Parkinsons Dis. 2025 Dec;15(8):1442-1451. doi: 10.1177/1877718X251371538. Epub 2025 Sep 2.

Pathophysiology and pharmacological management for sleep problems in Parkinson's disease

Falup-Pecurariu C, Ungureanu L, Murasan I, Diaconu S.

J Parkinsons Dis. 2025 Sep 2:1877718X251371945. doi: 10.1177/1877718X251371945. Online ahead of print.

The microbiota-brain connection in neurological diseases: the ubiquitous short-chain fatty acids

Bertin L, Bonazzi E, Facchin S, Lorenzon G, Maniero D, DE Barba C, Tomasulo A, Fortuna A, Zingone F, Barberio B, Savarino EV.

Minerva Gastroenterol (Torino). 2025 Sep;71(3):239-267. doi: 10.23736/S2724-5985.25.03866-5. Epub 2025 Sep 2.

Exploring the role of HIF-1α in pathogenesis of parkinson's disease and its potential as a therapeutic target

Kaur N, Aran KR.

Mol Biol Rep. 2025 Sep 2;52(1):858. doi: 10.1007/s11033-025-10944-y.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias